BioSpace News Archive

Armed with insights from substantive, real-world data, Blue Cross and Blue Shield plans that partner with Prime Therapeutics LLC (Prime) are now more effectively making data-driven decisions to mitigate the high costs of autoimmune therapies for inflammatory conditions and multiple sclerosis (MS).

Amyris, Inc. announced a 5-year partnership with Reese Witherspoon as global brand ambassador for Biossance®, one of the fastest growing clean and sustainable skincare brands in the world.

Semler Scientific, Inc. announced that its chief executive officer, Doug Murphy-Chutorian, and chief marketing officer, Dennis Rosenberg, will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, at 4:30 pm ET. Management will also participate in one-on-one calls with investors.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, has signed an agreement enabling multiple academic laboratories at Stanford University to access Twist Bioscience’s innovative antibody discovery and optimization services as well as its unique “Library of Libraries” for biologics discovery.

RushNet, Inc. (OTC PINK:RSHN) , recently acquired and D/B/A Chattahoochee Labs/HeliosDx , is pleased to announce a record-setting first quarter with total revenues of $1,252,000. The first quarter proved challenging on many fronts. As previously noted, we expanded our testing capacity, as well as our testing capabilities.

ERC-USA and the University of California, Irvine (UCI), today announce that the FDA has recommended early termination of the onging Phase 2 clinical trial titled ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma in a letter dated April 2, 2021 (https://clinicaltrials.gov/ct2/show/NCT01903330?term=Bota&draw=2&rank=3)

Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient has been dosed in the AFFINITY Study, a phase 2 clinical trial evaluating the efficacy and safety of atrasentan, a potent and selective inhibitor of the endothelin A receptor

AVM Biotechnology announced today that the first cohort has been fully enrolled in their clinical study (NCT04329728 “The WWRD Study”). All three patients had failed multiple prior therapies, and one had failed two transplants.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2021 on Wednesday, April 28, after the market closes.

Ironshore Pharmaceuticals Inc. announced the publication of an original paper in the Journal of Child and Adolescent Psychopharmacology that describes new data showing the effect of JORNAY PM® extended-release capsules CII on caregiver strain as measured by the Caregiver Strain Questionnaire.